The International Pharmaceutical Aerosol Consortium (IPAC) and its members support the EU’s goal of net carbon neutrality. As detailed in the attached Position Paper, we call on EU legislators to devise the phase-down of medical F-gases in the EU in a way that maintains access to critical medicines for patients, allows for adequate time for a truly sustainable transition to a new generation of propellants for…
IPA
International Pharmaceutical Aerosol Consortium
Industry association · United States · EU Transparency Register 602537137644-70
2
positions filed
in the 583 files tracked
1
legislative file
of 583 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1365 trade and business associations on this site, they rank #996 by legislative files engaged — a count of participation, not a measure of influence.
0.5
declared lobbying FTE
self-declared
€100K+
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2020
in the register since
Declares membership of
- IPAC is an associate member of the Alliance for Responsible Atmospheric Policy, please see: http://alliancepolicy.org…
Self-declared to the EU Transparency Register (snapshot 2 Sept 2026).
- Register category
- Trade and business associations
- Head office
- Washington, United states
Self-declared to the EU Transparency Register (snapshot 2 Sept 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track International in PolicySpeak: request access →
Work at International Pharmaceutical Aerosol Consortium? so we know who speaks for it.
Their record over time
International Pharmaceutical Aerosol Consortium filed 2 positions between 5 Sept 2020 and 24 Jun 2022, across 1 of the 583 legislative files tracked here, attaching a full position paper 2 times.
2020 · 1 filed2022 · 1 filed
What they argued
The International Pharmaceutical Aerosol Consortium (IPAC) represents major pharmaceutical companies – AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, and Kindeva – which research, develop, and manufacture products for the treatment of respiratory illnesses such as asthma and chronic obstructive pulmonary disease (COPD).
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put International Pharmaceutical Aerosol Consortium next to another organization. Same files, same register facts, side by side. Compare →
Is this your organization?
Everything on this page comes from International Pharmaceutical Aerosol Consortium’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.